Biotech Values

[jbog]

Revance says 'positive' Phase 2 RT002 study results published in journal

Revance Therapeutics, Inc. announced that results of a Phase 2 study of DaxibotulinumtoxinA for Injection to treat moderate-to-severe cervical dystonia have been published in the peer-reviewed journal Movement Disorders Clinical Practice.

These positive 24-week results from a Phase 2 open-label, dose-escalating study were announced in May 2017 and were formally presented at the 21st International Congress of Parkinson's Disease and Movement Disorders in June 2017.

The previously reported findings demonstrate that RT002 injectable provided clinically significant improvement in the signs and symptoms of CD as determined by reduction of the Toronto Western Spasmodic Torticollis Rating Scale-Total score from baseline.

In addition, RT002 was found to be generally safe and well-tolerated. "Cervical dystonia is a movement disorder characterized by involuntary movements of the head and neck resulting in abnormal twisting postures of the head that is frequently associated with pain. The treatment of choice for cervical dystonia is botulinum toxin injections.

Unfortunately, the drawback of this therapy, as currently available, is that patients must typically be re-treated at approximately three to four month intervals in order to maintain benefit," said trial investigator Joseph Jankovic, MD, Professor of Neurology and Distinguished Chair in Movement Disorders, Baylor College of Medicine.

"The data from the now published RT002 study indicated that this new formulation of botulinum toxin serotype A may significantly improve symptoms of cervical dystonia and have an impressive duration of benefit of 24 weeks, which is almost twice as long as the toxins currently available. The Phase 3 ASPEN cervical dystonia program will ultimately determine if the results of this Phase 2 study published in Movement Disorders Clinical Practice are replicated."

Read more at:
https://thefly.com/landingPageNews.php?id=2736511